Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy.

Date publication

décembre 2017

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NOEL Georges

Tous les auteurs :
Tallet AV, Dhermain F, Le Rhun E, Noël G, Kirova YM

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29045524

Résumé

Targeted therapies (TT) and immune checkpoint inhibitors (ICI) are currently modifying the landscape of metastatic cancer management and are increasingly used over the course of many cancers treatment. They allow long-term survival with controlled extra-cerebral disease, contributing to the increasing incidence of brain metastases (BMs). Radiation therapy remains the cornerstone of BMs treatment (either whole brain irradiation or stereotactic radiosurgery), and investigating the safety profile of radiation therapy combined with TT or ICI is of high interest. Discontinuing an efficient systemic therapy, when BMs irradiation is considered, might allow systemic disease progression and, on the other hand, the mechanisms of action of these two therapeutic modalities might lead to unexpected toxicities and/or greater efficacy, when combined.

Mots clés

Antibodies, Monoclonal, therapeutic use, Brain Neoplasms, drug therapy, Combined Modality Therapy, Cranial Irradiation, Humans, Immunotherapy, methods, Molecular Targeted Therapy, Radiosurgery

Référence

Ann. Oncol.. 2017 Dec 1;28(12):2962-2976